your initial deposit *subject to change and depends on individual circumstances.
Tissue Regenix is a company that focuses on delivering practical solutions to real clinical issues using its patented dCELL® process. The dCELL® Process removes foreign cells & DNA and provides a matrix that repopulates with patients own cells once its implanted - integrating into the patients own tissues.
Tissue Regenix to unveil pre-clinical trial data later this yearJuly 30 2012, 4:15pm
Tissue Regenix (LON:TRX) is to unveil data from a pre-clinical trial for the treatment of torn meniscus cartilage in knees later this year, chief executive Antony Odell told Bloomberg.
The regenerative tissue firm, which has pioneered a technology to swap worn out or damaged body tissue with replacements from a human donor or animal, added that a trial in humans will kick off in 2013.
Odell said that the company may file for approval for commercial launch as early as 2014.
The meniscus refers to either of the two parts of the knee’s cartilage, which provide structural support to the knee when it is put under pressure.
An injury to one of the ‘menisci’ is common, especially in sport, where it is often referred to as “torn cartilage”.
Tissue Regenix hopes its dCell treatment can revolutionise the recovery process for such injuries.
The dCell technology removes cellular material from animal tissue so that the recipient does not reject the implant.
The company is also working on replacement heart valves, skin and vascular patches using dCell in addition to cartilage and ligaments.
Shares in the company rose almost 7 per cent to 9.75 pence.